163 related articles for article (PubMed ID: 2260169)
1. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
Castro C; Sampaio RN; Marsden PD
Trans R Soc Trop Med Hyg; 1990; 84(3):362. PubMed ID: 2260169
[No Abstract] [Full Text] [Related]
2. Pentavalent antimonial-induced torsade de pointes.
Ortega-Carnicer J; Alcázar R; De la Torre M; Benezet J
J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610
[TBL] [Abstract][Full Text] [Related]
3. [Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
Castelló Viguer MT; Echánove Errazti I; Ridocci Soriano F; Esteban Esteban E; Atienza Fernández F; Cuesta Estellés G
Rev Esp Cardiol; 1999 Jul; 52(7):533-5. PubMed ID: 10439681
[TBL] [Abstract][Full Text] [Related]
4. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
[No Abstract] [Full Text] [Related]
5. [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV].
Trinchieri V; Ferone U; Monacelli M; Isceri L; Proietti F; Sorice F
Riv Eur Sci Med Farmacol; 1996; 18(2):49-51. PubMed ID: 9213843
[TBL] [Abstract][Full Text] [Related]
6. [Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Report of a case].
Cucé LC; Belda Júnior W; Dias MC
Rev Inst Med Trop Sao Paulo; 1990; 32(4):249-51. PubMed ID: 2101518
[TBL] [Abstract][Full Text] [Related]
7. [Meglumine antimoniate].
Silva JB
Rev Soc Bras Med Trop; 2001; 34(1):103-5. PubMed ID: 11340506
[No Abstract] [Full Text] [Related]
8. Severe leucopenia during treatment of visceral leishmaniasis.
Hiçsönmez G; Jama H; Ozsoylu S
Trans R Soc Trop Med Hyg; 1988; 82(3):417. PubMed ID: 3232176
[No Abstract] [Full Text] [Related]
9. [A case of urticaria during pentavalent antimony use in a patient with mucous leishmaniasis].
Oliveira MR; Marsden PD
Rev Soc Bras Med Trop; 1995; 28(3):287. PubMed ID: 7480927
[No Abstract] [Full Text] [Related]
10. [Symptomatic hypokalemia caused by meglumine antimoniate].
Bouvresse S; Matichard E; Mahé E; Marinho E; Soria A; Devillière M; Descamps V; Crickx B
Ann Dermatol Venereol; 2007 Apr; 134(4 Pt 1):387-8. PubMed ID: 17483764
[No Abstract] [Full Text] [Related]
11. [A fatal case of mucocutaneous leishmaniasis after pentavalent antimonial use].
Oliveira MC; Amorim RF; Freitas Rde A; Costa Ade L
Rev Soc Bras Med Trop; 2005; 38(3):258-60. PubMed ID: 15895180
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
Hantson P; Léonard ED; Crutzen-Fayt MC; Léonard A; Vandercam B; Delaere B; Mahieu P
Pharmacotherapy; 1996; 16(5):869-71. PubMed ID: 8888081
[TBL] [Abstract][Full Text] [Related]
13. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
Segura I; García-Bolao I
Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
[TBL] [Abstract][Full Text] [Related]
14. Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials.
Veiga JP; Wolff ER; Sampaio RN; Marsden PD
Lancet; 1983 Sep; 2(8349):569. PubMed ID: 6136717
[No Abstract] [Full Text] [Related]
15. [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds].
Veiga JP; Rosa TT; Kimachi T; Wolff ER; Sampaio RN; Gagliardi AR; Junqueira Júnior LF; Costa JM; Marsden PD
Rev Inst Med Trop Sao Paulo; 1985; 27(6):298-302. PubMed ID: 3014634
[No Abstract] [Full Text] [Related]
16. [Torsade de pointes secondary to treatment with pentavalent antimonial drugs].
Temprano Vázquez S; García Salazar MA; Jiménez Martín MJ; López Martínez J
Med Clin (Barc); 1998 May; 110(18):717. PubMed ID: 9656226
[No Abstract] [Full Text] [Related]
17. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
Kuyucu N; Kara C; Bakirtaç A; Teziç T
Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
[TBL] [Abstract][Full Text] [Related]
19. [The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis].
Sampaio RN; de Paula CD; Sampaio JH; Furtado Rde S; Leal PP; Rosa TT; Rodrigues ME; Veiga JP
Rev Soc Bras Med Trop; 1997; 30(6):457-63. PubMed ID: 9463192
[TBL] [Abstract][Full Text] [Related]
20. Possible links between sickle cell crisis and pentavalent antimony.
Garcerant D; Rubiano L; Blanco V; Martinez J; Baker NC; Craft N
Am J Trop Med Hyg; 2012 Jun; 86(6):1057-61. PubMed ID: 22665619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
